Fujifilm's CDMO arm plots massive $2B plant in the US for broad range of therapeutics
Buoyed by interest from major Covid-19 vaccine makers for its viral-vector capabilities, Fujifilm’s CDMO arm has looked to rapidly build its US footprint to meet demand. Now, just days after unveiling plans for a new HQ in the Boston area, Fujifilm is putting down a massive down payment on another US site.
Fujifilm will spend $2 billion by 2025 to build a large-scale cell culture production plant near one of its existing facilities as the Japanese CDMO looks to expand and scale its US footprint. The newest plant will help boost Fujifilm Diosynth Biotechnologies’ cumulative growth by 20% by March 2026, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
